|
US5216026A
(en)
|
1990-07-17 |
1993-06-01 |
Eli Lilly And Company |
Antitumor compositions and methods of treatment
|
|
DE19540995A1
(de)
|
1995-11-03 |
1997-05-07 |
Hoechst Ag |
Substituierte Sulfonimidamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
|
|
DK1270565T3
(da)
|
1997-01-29 |
2004-10-04 |
Pfizer |
4-substitueret furan-2-sulfonamid og dets anvendelse i fremstillingen af sulfonylurinstofderivater
|
|
BR0014003A
(pt)
|
1999-09-14 |
2002-05-21 |
Pfizer Prod Inc |
Tratamento de combinação com compostos de diaril sufonil uréia e il-1ra
|
|
AU2002341321A1
(en)
|
2001-11-30 |
2003-06-10 |
Pfizer Products Inc. |
Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation
|
|
CA2789665C
(en)
|
2010-02-22 |
2020-06-16 |
Askat Inc. |
Use of ep4 receptor antagonists in the treatment of il-23 mediated diseases
|
|
TW201311693A
(zh)
|
2011-09-02 |
2013-03-16 |
Kyowa Hakko Kirin Co Ltd |
化學激活激素受體活性調節劑
|
|
WO2014190015A1
(en)
|
2013-05-21 |
2014-11-27 |
Virginia Commonwealth University |
Cryopyrin inhibitors for preventing and treating inflammation
|
|
JP6929792B2
(ja)
|
2015-02-16 |
2021-09-01 |
ザ ユニバーシティ オブ クィーンズランド |
スルホニル尿素及び関連化合物並びにその使用
|
|
FR3046933B1
(fr)
|
2016-01-25 |
2018-03-02 |
Galderma Research & Development |
Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
|
|
BR112018016671A2
(pt)
|
2016-02-16 |
2018-12-26 |
The University Of Queensland |
sulfonilureias e compostos relacionados e uso do mesmo
|
|
US11447460B2
(en)
|
2016-04-18 |
2022-09-20 |
Novartis Ag |
Compounds and compositions for treating conditions associated with NLRP activity
|
|
MA44729A
(fr)
|
2016-04-18 |
2021-05-12 |
Novartis Ag |
Composés et compositions pour traiter des états associés à une activité de nlrp
|
|
UA126675C2
(uk)
|
2017-01-23 |
2023-01-11 |
Дженентек, Інк. |
Хімічні сполуки як інгібітори активності інтерлейкіну-1
|
|
US11840543B2
(en)
|
2017-05-24 |
2023-12-12 |
The University Of Queensland |
Compounds and uses
|
|
EP3634951B8
(en)
|
2017-06-09 |
2024-08-21 |
Zydus Lifesciences Limited |
Novel substituted sulfoximine compounds
|
|
CN110914256A
(zh)
|
2017-07-07 |
2020-03-24 |
英夫拉索姆有限公司 |
新颖磺酰胺羧酰胺化合物
|
|
EP3649112A1
(en)
|
2017-07-07 |
2020-05-13 |
Inflazome Limited |
Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
|
|
JP7412328B2
(ja)
|
2017-07-24 |
2024-01-12 |
ノバルティス アーゲー |
Nlrp活性に関連する状態を治療するための化合物及び組成物
|
|
TW201910317A
(zh)
|
2017-08-15 |
2019-03-16 |
愛爾蘭商英弗雷佐姆有限公司 |
新穎化合物
|
|
WO2019034697A1
(en)
|
2017-08-15 |
2019-02-21 |
Inflazome Limited |
NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS
|
|
EP3668862A1
(en)
|
2017-08-15 |
2020-06-24 |
Inflazome Limited |
Novel sulfonamide carboxamide compounds
|
|
AU2018317800A1
(en)
|
2017-08-15 |
2020-02-13 |
Inflazome Limited |
Novel sulfonamide carboxamide compounds
|
|
TW201910314A
(zh)
|
2017-08-15 |
2019-03-16 |
愛爾蘭商英弗雷佐姆有限公司 |
新穎化合物
|
|
WO2019034693A1
(en)
|
2017-08-15 |
2019-02-21 |
Inflazome Limited |
SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
|
|
MX2020001776A
(es)
|
2017-08-15 |
2020-03-24 |
Inflazome Ltd |
Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
|
|
WO2019043610A1
(en)
|
2017-08-31 |
2019-03-07 |
Cadila Healthcare Limited |
NEW SUBSTITUTED SULFONYLUREA DERIVATIVES
|
|
US11623922B2
(en)
|
2017-10-03 |
2023-04-11 |
Inflazome Limited |
Compounds
|
|
WO2019092171A1
(en)
|
2017-11-09 |
2019-05-16 |
Inflazome Limited |
Novel sulfonamide carboxamide compounds
|
|
WO2019092172A1
(en)
|
2017-11-09 |
2019-05-16 |
Inflazome Limited |
Novel sulfonamide carboxamide compounds
|
|
CN111315733A
(zh)
|
2017-11-09 |
2020-06-19 |
英夫拉索姆有限公司 |
新颖磺酰胺甲酰胺化合物
|
|
GB201721185D0
(en)
|
2017-12-18 |
2018-01-31 |
Nodthera Ltd |
Sulphonyl urea derivatives
|
|
GB201803393D0
(en)
|
2018-03-02 |
2018-04-18 |
Inflazome Ltd |
Novel compounds
|
|
GB201803394D0
(en)
|
2018-03-02 |
2018-04-18 |
Inflazome Ltd |
Novel compounds
|
|
WO2019166619A1
(en)
|
2018-03-02 |
2019-09-06 |
Inflazome Limited |
Novel compounds
|
|
GB201806578D0
(en)
|
2018-04-23 |
2018-06-06 |
Inflazome Ltd |
Novel compound
|
|
JP2021529187A
(ja)
|
2018-07-03 |
2021-10-28 |
ノバルティス アーゲー |
Nlrpモジュレータ
|
|
JP2021529780A
(ja)
|
2018-07-03 |
2021-11-04 |
ノバルティス アーゲー |
Nlrp3アンタゴニストを使用するtnf阻害剤に対して抵抗性の対象のための治療の方法又は治療を選択する方法
|
|
AR117951A1
(es)
|
2018-07-20 |
2021-09-08 |
Gruenenthal Gmbh |
Derivados de triazolquinoxalina adicionalmente sustituidos
|
|
MX2021000660A
(es)
|
2018-07-20 |
2021-03-25 |
Hoffmann La Roche |
Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1.
|
|
MA53172A
(fr)
|
2018-07-20 |
2021-05-26 |
Hoffmann La Roche |
Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1
|
|
SG11202101480XA
(en)
|
2018-08-15 |
2021-03-30 |
Inflazome Ltd |
Novel sulfonamideurea compounds
|
|
GB201902327D0
(en)
|
2019-02-20 |
2019-04-03 |
Inflazome Ltd |
Novel compounds
|
|
GB201817038D0
(en)
|
2018-10-19 |
2018-12-05 |
Inflazome Ltd |
Novel processes
|
|
US20230011652A1
(en)
|
2018-10-24 |
2023-01-12 |
Novartis Ag |
Compounds and compositions for treating conditions associated with nlrp activity
|
|
CR20210235A
(es)
|
2018-11-13 |
2021-06-30 |
Novartis Ag |
Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp
|
|
CN113166081A
(zh)
|
2018-11-13 |
2021-07-23 |
诺华股份有限公司 |
用于治疗与nlrp活性相关的病症的化合物和组合物
|
|
CN113286784A
(zh)
*
|
2018-11-16 |
2021-08-20 |
诺华股份有限公司 |
用于治疗与nlrp活性相关的病症的化合物和组合物
|
|
GB201819083D0
(en)
|
2018-11-23 |
2019-01-09 |
Inflazome Ltd |
Novel compounds
|
|
US20220227707A1
(en)
|
2019-01-22 |
2022-07-21 |
Novartis Ag |
Compounds and compositions for treating conditions associated with nlrp activity
|
|
JP2022518260A
(ja)
|
2019-01-23 |
2022-03-14 |
ノバルティス アーゲー |
Nlrp活性に関連する状態を治療するためのスルホンイミドアミド化合物及び組成物
|
|
KR20240104214A
(ko)
|
2019-03-29 |
2024-07-04 |
메디뮨 리미티드 |
화합물 및 이의 접합체
|
|
CN114008030A
(zh)
|
2019-06-21 |
2022-02-01 |
Ac免疫有限公司 |
用作nlrp3调节剂的稠合的1,2-噻唑和1,2-噻嗪
|
|
WO2021002887A1
(en)
|
2019-07-02 |
2021-01-07 |
Novartis Inflammasome Research, Inc. |
Gut-targeted nlrp3 antagonists and their use in therapy
|
|
CA3165238A1
(en)
|
2019-12-19 |
2021-06-24 |
Jacobio Pharmaceuticals Co., Ltd. |
Kras mutant protein inhibitors
|
|
TWI785474B
(zh)
|
2020-01-22 |
2022-12-01 |
大陸商北京加科思新藥研發有限公司 |
用作選擇性Aurora A抑制劑的新型雜環化合物
|
|
AR121078A1
(es)
|
2020-01-22 |
2022-04-13 |
Chugai Pharmaceutical Co Ltd |
Derivados de arilamida con actividad antitumoral
|
|
BR112022014480A2
(pt)
|
2020-01-22 |
2022-09-13 |
Hoffmann La Roche |
Compostos, composições farmacêutica, método para tratar um distúrbio em um paciente, usos de um composto e de uma composição farmacêutica e kit
|
|
IL295120A
(en)
|
2020-01-29 |
2022-09-01 |
Univ Illes Balears |
alpha-hydroxylated fatty-acid metabolites, their medical uses and their use as biomarkers
|
|
US20230203064A1
(en)
|
2020-04-23 |
2023-06-29 |
Janssen Pharmaceutica Nv |
Tricyclic compounds as inhibitors of nlrp3
|
|
WO2021219784A1
(en)
|
2020-04-30 |
2021-11-04 |
Janssen Pharmaceutica Nv |
New triazinoindole compounds
|
|
IL312785B2
(en)
|
2020-05-19 |
2026-06-01 |
Cybin Irl Ltd |
Deuterated tryptamine derivatives and methods of use
|
|
KR20230016658A
(ko)
|
2020-05-28 |
2023-02-02 |
얀센 파마슈티카 엔.브이. |
화합물
|
|
US12624010B2
(en)
|
2020-06-19 |
2026-05-12 |
Ac Immune Sa |
Dihydrooxazole and thiourea derivatives modulating the NLRP3 inflammasome pathway
|
|
IL277528B
(en)
|
2020-09-22 |
2022-05-01 |
Ag Plenus Ltd |
Herbicidal compounds and methods of their use
|
|
US20240043450A1
(en)
|
2020-09-24 |
2024-02-08 |
Janssen Pharmaceutica Nv |
New compound
|
|
KR20230152016A
(ko)
|
2021-03-04 |
2023-11-02 |
얀센 파마슈티카 엔브이 |
Nlrp3을 조절하는 4-알콕시-6-옥소-피리다진 유도체
|
|
CA3212725A1
(en)
|
2021-04-29 |
2022-11-03 |
Daniel Oehlrich |
Phthalazinone derivatives as nlrp3 inflammasome inhibitors
|
|
CN116917282B
(zh)
|
2021-05-10 |
2026-08-11 |
康百达(四川)生物医药科技有限公司 |
酰胺衍生物及其应用
|
|
WO2023275230A1
(en)
|
2021-07-01 |
2023-01-05 |
Janssen Pharmaceutica Nv |
5-oxo-pyrido[2,3-d]pyridazin-6(5h)-yl acetamides
|